{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:57:22Z","timestamp":1790085442244,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Siftung Gyn\u00e4kologische Onkologie"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Presence of circulating tumor cells (CTCs) is associated with impaired clinical outcome in several solid cancers. Limited data are available on the significance of CTCs in gynaecological malignancies. The aims of the present study were to evaluate the dynamics of CTCs in patients with ovarian, fallopian tube and peritoneal cancer during chemotherapy and to assess their clinical relevance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>43 patients with ovarian, fallopian tube and peritoneal cancer were included into this prospective study. Patients received chemotherapy according to national guidelines. CTC analysis was performed using the CellSearch system prior to chemotherapy, after three and six cycles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In 26% of the patients,\u2009\u2265\u20091CTC per 7.5\u00a0ml of blood was detected at baseline (17% of patients with de novo disease, compared to 35% in recurrent patients). Presence of CTCs did not correlate with other factors. After three cycles of therapy, CTC positivity rate declined to 4.8%. After six cycles, no patient showed persistent CTCs. Patients with\u2009\u2265\u20091 CTC at baseline had significantly shorter overall survival and progression-free survival compared to CTC-negative patients (OS: median 3.1\u00a0months vs. not reached,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006, PFS: median 3.1 vs. 23.1\u00a0months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). When only the subgroup with newly diagnosed cancer was considered, the association between CTC status and survival was not significant (OS: mean 17.4 vs. 29.0\u00a0months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.192, PFS: 14.3 vs. 26.9\u00a0months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.085). Presence of\u2009\u2265\u20091 CTC after three cycles predicted shorter OS in the entire patient cohort (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hematogenous tumor cell dissemination is a common phenomenon in ovarian, fallopian tube and peritoneal cancer. CTC status before start of systemic therapy correlates with clinical outcome. Chemotherapy leads to a rapid decline in CTC counts; further research is needed to evaluate the clinical value of CTC monitoring after therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00404-020-05477-7","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T11:04:49Z","timestamp":1583492689000},"page":"1027-1035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer"],"prefix":"10.1007","volume":"301","author":[{"given":"Malgorzata","family":"Banys-Paluchowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Fehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Paluchowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Meier-Stiegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Wallach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kaczerowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"key":"5477_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin 68:284\u2013296. https:\/\/doi.org\/10.3322\/caac.21456","journal-title":"CA Cancer J Clin"},{"key":"5477_CR2","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1158\/1078-0432.CCR-15-1603","volume":"22","author":"WJ Janni","year":"2016","unstructured":"Janni WJ, Rack B, Terstappen LW, Pierga JY, Taran FA, Fehm T, Hall C, de Groot MR, Bidard FC, Friedl TW et al (2016) Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin Cancer Res 22:2583\u20132593. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1603","journal-title":"Clin Cancer Res"},{"key":"5477_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrurol.2018.25","volume":"15","author":"C Hille","year":"2018","unstructured":"Hille C, Pantel K (2018) Prostate cancer: circulating tumour cells in prostate cancer. Nat Rev Urol 15:265\u2013266. https:\/\/doi.org\/10.1038\/nrurol.2018.25","journal-title":"Nat Rev Urol"},{"key":"5477_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3389\/fonc.2018.00311","volume":"8","author":"J Kapeleris","year":"2018","unstructured":"Kapeleris J, Kulasinghe A, Warkiani ME, Vela I, Kenny L, O'Byrne K, Punyadeera C (2018) The prognostic role of circulating tumor cells (CTCs) in lung cancer. Front Oncol 8:311. https:\/\/doi.org\/10.3389\/fonc.2018.00311","journal-title":"Front Oncol"},{"key":"5477_CR5","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/IGC.0b013e3181a23c4c","volume":"19","author":"M Banys","year":"2009","unstructured":"Banys M, Solomayer EF, Becker S, Krawczyk N, Gardanis K, Staebler A, Neubauer H, Wallwiener D, Fehm T (2009) Disseminated tumor cells in bone marrow may affect prognosis of patients with gynecologic malignancies. Int J Gynecol Cancer 19:948\u2013952. https:\/\/doi.org\/10.1111\/IGC.0b013e3181a23c4c","journal-title":"Int J Gynecol Cancer"},{"key":"5477_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/IGC.0b013e3182907109","volume":"23","author":"T Fehm","year":"2013","unstructured":"Fehm T, Banys M, Rack B, Janni W, Marth C, Blassl C, Hartkopf A, Trope C, Kimmig R, Krawczyk N et al (2013) Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer. Int J Gynecol Cancer 23:839\u2013845. https:\/\/doi.org\/10.1097\/IGC.0b013e3182907109","journal-title":"Int J Gynecol Cancer"},{"key":"5477_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ygyno.2011.05.028","volume":"122","author":"A Poveda","year":"2011","unstructured":"Poveda A, Kaye SB, McCormack R, Wang S, Parekh T, Ricci D, Lebedinsky CA, Tercero JC, Zintl P, Monk BJ (2011) Circulating tumor cells predict progression free survival and overall survival in patients with relapsed\/recurrent advanced ovarian cancer. Gynecol Oncol 122:567\u2013572. https:\/\/doi.org\/10.1016\/j.ygyno.2011.05.028","journal-title":"Gynecol Oncol"},{"key":"5477_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","volume":"93","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93:387\u2013391. https:\/\/doi.org\/10.1038\/sj.bjc.6602678","journal-title":"Br J Cancer"},{"key":"5477_CR9","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1097\/IGC.0b013e318216cb91","volume":"21","author":"B Aktas","year":"2011","unstructured":"Aktas B, Kasimir-Bauer S, Heubner M, Kimmig R, Wimberger P (2011) Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy. Int J Gynecol Cancer 21:822\u2013830. https:\/\/doi.org\/10.1097\/IGC.0b013e318216cb91","journal-title":"Int J Gynecol Cancer"},{"key":"5477_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/cncr.10250","volume":"94","author":"C Marth","year":"2002","unstructured":"Marth C, Kisic J, Kaern J, Trope C, Fodstad O (2002) Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. Cancer 94:707\u2013712","journal-title":"Cancer"},{"key":"5477_CR11","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/j.1525-1438.2007.00920.x","volume":"17","author":"C Schindlbeck","year":"2007","unstructured":"Schindlbeck C, Hantschmann P, Zerzer M, Jahns B, Rjosk D, Janni W, Rack B, Sommer H, Friese K (2007) Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow. Int J Gynecol Cancer 17:1047\u20131055. https:\/\/doi.org\/10.1111\/j.1525-1438.2007.00920.x","journal-title":"Int J Gynecol Cancer"},{"key":"5477_CR12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1200\/JCO.2001.19.2.368","volume":"19","author":"S Braun","year":"2001","unstructured":"Braun S, Schindlbeck C, Hepp F, Janni W, Kentenich C, Riethmuller G, Pantel K (2001) Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse. J Clin Oncol 19:368\u2013375","journal-title":"J Clin Oncol"},{"key":"5477_CR13","doi-asserted-by":"publisher","first-page":"26454","DOI":"10.18632\/oncotarget.8524","volume":"7","author":"I Chebouti","year":"2016","unstructured":"Chebouti I, Blassl C, Wimberger P, Neubauer H, Fehm T, Kimmig R, Kasimir-Bauer S (2016) Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis? Oncotarget 7:26454\u201326464. https:\/\/doi.org\/10.18632\/oncotarget.8524","journal-title":"Oncotarget"},{"key":"5477_CR14","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1200\/JCO.2005.08.140","volume":"23","author":"M Cristofanilli","year":"2005","unstructured":"Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC et al (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23:1420\u20131430. https:\/\/doi.org\/10.1200\/JCO.2005.08.140","journal-title":"J Clin Oncol"},{"key":"5477_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10555-012-9398-0","volume":"32","author":"FC Bidard","year":"2013","unstructured":"Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabieres C, Janni W, Messina C, Paoletti C, Muller V, Hayes DF et al (2013) Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 32:179\u2013188. https:\/\/doi.org\/10.1007\/s10555-012-9398-0","journal-title":"Cancer Metastasis Rev"},{"key":"5477_CR16","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1200\/JCO.2014.56.2561","volume":"32","author":"JB Smerage","year":"2014","unstructured":"Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL et al (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483\u20133489. https:\/\/doi.org\/10.1200\/JCO.2014.56.2561","journal-title":"J Clin Oncol"},{"key":"5477_CR17","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/annonc\/mdn786","volume":"20","author":"SJ Cohen","year":"2009","unstructured":"Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC et al (2009) Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20:1223\u20131229. https:\/\/doi.org\/10.1093\/annonc\/mdn786","journal-title":"Ann Oncol"},{"key":"5477_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ygyno.2008.09.021","volume":"112","author":"T Fan","year":"2009","unstructured":"Fan T, Zhao Q, Chen JJ, Chen WT, Pearl ML (2009) Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol 112:185\u2013191. https:\/\/doi.org\/10.1016\/j.ygyno.2008.09.021","journal-title":"Gynecol Oncol"},{"key":"5477_CR19","first-page":"4133","volume":"23","author":"J Sehouli","year":"2003","unstructured":"Sehouli J, Konsgen D, Nimpsch R, Stengel D, Oskay G, Mustea A, Oertel J, Lichtenegger W (2003) Prognostic significance of epithelial cells in the blood of patients with gynaecological malignancies. Anticancer Res 23:4133\u20134140","journal-title":"Anticancer Res"},{"key":"5477_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/BCTT.S26431","volume":"4","author":"M Banys","year":"2012","unstructured":"Banys M, Hartkopf AD, Krawczyk N, Kaiser T, Meier-Stiegen F, Fehm T, Neubauer H (2012) Dormancy in breast cancer. Breast Cancer 4:183\u2013191. https:\/\/doi.org\/10.2147\/BCTT.S26431","journal-title":"Breast Cancer"},{"key":"5477_CR21","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1002\/1097-0142(19871001)60:7<1561::AID-CNCR2820600725>3.0.CO;2-V","volume":"60","author":"J Dauplat","year":"1987","unstructured":"Dauplat J, Hacker NF, Nieberg RK, Berek JS, Rose TP, Sagae S (1987) Distant metastases in epithelial ovarian carcinoma. Cancer 60:1561\u20131566","journal-title":"Cancer"},{"key":"5477_CR22","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1159\/000492521","volume":"48","author":"X Zhang","year":"2018","unstructured":"Zhang X, Li H, Yu X, Li S, Lei Z, Li C, Zhang Q, Han Q, Li Y, Zhang K et al (2018) Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker. Cell Physiol Biochem 48:1983\u20131994. https:\/\/doi.org\/10.1159\/000492521","journal-title":"Cell Physiol Biochem"},{"key":"5477_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3389\/fonc.2013.00251","volume":"3","author":"J Chien","year":"2013","unstructured":"Chien J, Kuang R, Landen C, Shridhar V (2013) Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol 3:251. https:\/\/doi.org\/10.3389\/fonc.2013.00251","journal-title":"Front Oncol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05477-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-020-05477-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05477-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T19:11:35Z","timestamp":1614971495000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-020-05477-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["5477"],"URL":"https:\/\/doi.org\/10.1007\/s00404-020-05477-7","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,6]]},"assertion":[{"value":"1 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study were in accordance with the ethical standard of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the local ethical committees of participation institutions (September, 1<sup>st<\/sup> 2015; approval number: PV5061, Ethikkommission der \u00c4rztekammer Hamburg).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}